drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-NK cell infusion)
drug_description
Gene-modified natural killer cells engineered with a chimeric antigen receptor targeting CLL1 (CLEC12A) to recognize and kill CLL1+ AML cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic iPSC-derived natural killer cells engineered with a chimeric antigen receptor targeting CLL1 (CLEC12A) bind CLL1 on AML blasts. CAR engagement activates NK effector functions, inducing targeted cytotoxicity (perforin/granzyme) and cytokine release to eliminate CLL1+ leukemic cells while sparing CLL1-negative hematopoietic stem cells.
drug_name
CLL1 CAR-NK cells (iPSC-derived, allogeneic)
nct_id_drug_ref
NCT06027853